CN Stock MarketDetailed Quotes

Chengdu Kanghong Pharmaceutical Group (002773)

Watchlist
  • 33.31
  • -0.20-0.60%
Trading Jan 16 11:04 CST
30.69BMarket Cap24.55P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Chengdu Kanghong Pharmaceutical Group (002773) Revenue Breakdown Overview

By Product

Currency:CNY
2025/H1
Stock NameRevenueRatio
Biological drugs1.35B54.83%
Chinese patent medicine797.23M32.49%
Chemical drugs306.75M12.50%
Other3.61M0.15%
Other business659.04K0.03%

By Industry

Currency:CNY
2025/H1
Stock NameRevenueRatio
Pharmaceutical manufacturing2.45B99.97%
Other business659.04K0.03%

By Country/Region

Currency:CNY
2025/H1
Stock NameRevenueRatio
East China665.94M27.14%
South China626.62M25.54%
Southwest428.79M17.48%
North China320.47M13.06%
Northwest225.99M9.21%
Northeast China184.8M7.53%
Other business659.04K0.03%
Overseas387.6K0.02%
View all

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
HK Tech and Internet Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +17.16%
Sample Name
Sample Code
 +13.79%
Sample Name
Sample Code
 +13.65%
4
BIDU-SW
09888
+6.40%
5
JD HEALTH
06618
+4.31%
View More
Nancy Pelosi Portfolio
No. Symbol % Chg
Sample Name
Sample Code
 +6.63%
Sample Name
Sample Code
 +3.27%
Sample Name
Sample Code
 +2.15%
4
NVIDIA
NVDA
+2.13%
5
Broadcom
AVGO
+0.92%
Will the 'tariff stick' strike again? Will the market remain 'reactive'?
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -